Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
St. Louis University Hospital
mi
from
St. Louis, MO
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
St. Louis University Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Columbia University
mi
from
New York, NY
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Baylor Health Care System
mi
from
Dallas, TX
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Baylor Health Care System
mi
from
Dallas, TX
Click here to add this to my saved trials
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Encino, CA
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Encino, CA
Click here to add this to my saved trials
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Minneapolis, MN
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Temsirolimus as Second-line Therapy in HCC
A Phase II Study of Temsirolimus as Second-line Therapy in Patients With Advanced, Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/13/2012
Boston Baskin Cancer Foundation
mi
from
Memphis, TN
Temsirolimus as Second-line Therapy in HCC
A Phase II Study of Temsirolimus as Second-line Therapy in Patients With Advanced, Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/13/2012
Boston Baskin Cancer Foundation
mi
from
Memphis, TN
Click here to add this to my saved trials
Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Pilot Study to Assess Safety and Efficacy of an Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Status: Enrolling
Updated:  12/18/2012
Weill Medical College of Cornell University
mi
from
New York, NY
Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Pilot Study to Assess Safety and Efficacy of an Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Status: Enrolling
Updated: 12/18/2012
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Status: Enrolling
Updated:  1/8/2013
California Pacific Medical Center
mi
from
San Francisco, CA
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Status: Enrolling
Updated: 1/8/2013
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Status: Enrolling
Updated:  1/8/2013
University of Miami
mi
from
Miami, FL
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Status: Enrolling
Updated: 1/8/2013
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Status: Enrolling
Updated:  1/8/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Status: Enrolling
Updated: 1/8/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Status: Enrolling
Updated:  1/8/2013
Univ of North Carolina
mi
from
Chapel Hill, NC
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Status: Enrolling
Updated: 1/8/2013
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Status: Enrolling
Updated:  1/8/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Status: Enrolling
Updated: 1/8/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
ALLPS VERSUS PVO Randomized Controlled Trial
ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS) Versus Conventional Portal Vein Occlusion (PVO) for Resection of Liver Tumors Unresectable in One Step - a Randomized Controlled Trial
Status: Enrolling
Updated:  1/23/2013
Washington University
mi
from
St. Louis, MO
ALLPS VERSUS PVO Randomized Controlled Trial
ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS) Versus Conventional Portal Vein Occlusion (PVO) for Resection of Liver Tumors Unresectable in One Step - a Randomized Controlled Trial
Status: Enrolling
Updated: 1/23/2013
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Interleukin 13 PE for Adults With Advanced Cancers
A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
Status: Enrolling
Updated:  2/1/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Interleukin 13 PE for Adults With Advanced Cancers
A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
Status: Enrolling
Updated: 2/1/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin
Status: Enrolling
Updated:  3/8/2013
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin
Status: Enrolling
Updated: 3/8/2013
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin
Status: Enrolling
Updated:  3/8/2013
White River Junction VA Medical Center
mi
from
White River Junction, VT
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin
Status: Enrolling
Updated: 3/8/2013
White River Junction VA Medical Center
mi
from
White River Junction, VT
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
Moores University of California San Diego Cancer Center
mi
from
La Jolla, CA
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
Moores University of California San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
California Pacific Medical Center
mi
from
San Francisco, CA
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
Stanford Hospital and Clinics
mi
from
Stanford, CA
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
University of Chicago Medical Center
mi
from
Chicago, IL
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
Billings Clinic
mi
from
Billings, MT
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
Billings Clinic
mi
from
Billings, MT
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
Saint Joseph's Hospital
mi
from
Paterson, NJ
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
Saint Joseph's Hospital
mi
from
Paterson, NJ
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
Montefiore Medical Center
mi
from
Bronx, NY
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
Gabrail Cancer Center
mi
from
Canton, OH
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
The Methodist Hospital Department of Surgery
mi
from
Houston, TX
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
The Methodist Hospital Department of Surgery
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated:  3/19/2013
Benaroya Research Institute
mi
from
Seattle, WA
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Status: Enrolling
Updated: 3/19/2013
Benaroya Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)
An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7
Status: Enrolling
Updated:  3/29/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)
An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7
Status: Enrolling
Updated: 3/29/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With HCC
The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With Hepatocellular Carcinoma: a Muti-center Randomized Clinical Trail.
Status: Enrolling
Updated:  4/1/2013
National Cancer Institute, NIH, US
mi
from
Bethesda, MD
The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With HCC
The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With Hepatocellular Carcinoma: a Muti-center Randomized Clinical Trail.
Status: Enrolling
Updated: 4/1/2013
National Cancer Institute, NIH, US
mi
from
Bethesda, MD
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Clearview Cancer Center
mi
from
Huntsville, AL
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Clearview Cancer Center
mi
from
Huntsville, AL
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Radiology Associates of Sacramento/Sutter Cancer Center
mi
from
Sacramento, CA
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Radiology Associates of Sacramento/Sutter Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Emory University
mi
from
Atlanta, GA
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Northside Hospital/GA Cancer Specialists
mi
from
Atlanta, GA
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Northside Hospital/GA Cancer Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
University of Louisville
mi
from
Louisville, KY
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Hematology and Oncology Assoc. at Bridgeport
mi
from
Tupelo, MS
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Hematology and Oncology Assoc. at Bridgeport
mi
from
Tupelo, MS
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Washington University/Alvin J. Siteman Cancer Center
mi
from
St. Louis, MO
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Washington University/Alvin J. Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Providence Portland Medical Center/Providence Cancer Center
mi
from
Portland, OR
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Providence Portland Medical Center/Providence Cancer Center
mi
from
Portland, OR
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Froedtert Memorial Lutheran Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated:  4/17/2013
Hospital Italiano de Buenos Aires
mi
from
Buenos Aires,
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Status: Enrolling
Updated: 4/17/2013
Hospital Italiano de Buenos Aires
mi
from
Buenos Aires,
Click here to add this to my saved trials
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated:  4/24/2013
New York Presbyterian-Weill Cornell Medical Center
mi
from
New York, NY
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated: 4/24/2013
New York Presbyterian-Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated:  4/24/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated: 4/24/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated:  4/24/2013
Virginia Mason Medical Center
mi
from
Seattle, WA
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated: 4/24/2013
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated:  4/24/2013
Yale-New Haven Hospital
mi
from
New Haven, CT
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
Status: Enrolling
Updated: 4/24/2013
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
University Of Florida Hepatology
mi
from
Gainesville, FL
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
University Of Florida Hepatology
mi
from
Gainesville, FL
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Mayo Clinic
mi
from
Jacksonville, FL
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Florida Hospital Transplant Center
mi
from
Orlando, FL
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Florida Hospital Transplant Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Tampa General Hospital
mi
from
Tampa, FL
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Loyola University Medical Center
mi
from
Proviso, IL
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Loyola University Medical Center
mi
from
Proviso, IL
Click here to add this to my saved trials